What Rex Medical does

Rex Medical is a privately held medical device design, development, and manufacturing company headquartered in Conshohocken, Pennsylvania. Founded in 1999, the company develops minimally invasive medical devices targeted at cardiovascular, venous access, endosurgery, and oncology markets. Following the January 2016 divestiture of three vascular products (OptionELITE Retrievable Vena Cava Filter, CLEANER Rotational Thrombectomy System, and UltraStream Chronic Hemodialysis Catheter) to Argon Medical Devices, Rex Medical has concentrated commercial activity on its flagship REVOLUTION™ Peripheral Atherectomy System, an FDA 510(k)-cleared low-profile rotational atherectomy device operating at 140,000 RPM with continuous mechanical aspiration for both above-the-knee and below-the-knee peripheral interventions.

The REVOLUTION™ system is built around a front cutting mechanism with .014 inch over-the-wire capability, effective on multiple plaque morphologies ranging from thrombus and soft plaque to severely calcified lesions and chronic total occlusions. The device is powered by a compact 72-watt supply similar in size to a laptop charger, eliminating the need for capital equipment and enabling rapid setup in office interventional suites and outpatient surgery centers. Rex Medical holds ISO 13485 certification and based its U.S. regulatory clearance on the REVEAL IDE clinical trial, which enrolled 121 patients across 17 U.S. sites and met all prespecified primary and secondary safety and effectiveness endpoints.

Rex Medical generates revenue through direct hardware sales of REVOLUTION™ catheters to hospitals, outpatient surgery centers, and office interventional suites, sold via an enterprise field sales motion targeting interventional cardiologists, vascular surgeons, and interventional radiologists. The company has no external funding rounds disclosed, no parent company, and operates as Rex Medical, L.P. — a Pennsylvania limited partnership. Leadership is anchored by President Lindsay L. Carter. Geographic footprint is U.S.-only at present, with CE Mark review (anticipated Q4 2019) representing the principal near-term international expansion lever.

Name

Rex Medical

Legal name

Rex Medical, L.P.

Website

https://rexmedical.com

Company type

Private

Founded year

1999

Operating status

Operating

Headcount range

11–50 employees

Short description

Rex Medical is a privately held medical device company that designs and manufactures the FDA-cleared REVOLUTION™ Peripheral Atherectomy System, serving interventional cardiologists and vascular specialists treating peripheral artery disease in U.S. hospitals, ASCs, and office interventional suites.

Ownership category

akta.pro rank

Product category

Peripheral Vascular Medical Devices

NAICS

Surgical Appliance and Supplies Manufacturing (339113)

SIC

Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Open & Minimally Invasive Surgical Instruments (Handheld, Laparoscopic, MIS) (HLAHADAA)

Keywords

• Peripheral atherectomy devices
• Minimally invasive medical devices
• Cardiovascular medical devices
• Thrombus removal systems
• Vascular intervention equipment

Headquarters

HQ city

Conshohocken

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Supply Chain, Operations, Marketing or Sales

Revenue model

1. Medical Device Sales: Rex Medical generates revenue through the sale of its REVOLUTION™ Peripheral Atherectomy System and related consumable medical devices. The company develops, manufactures, and markets innovative, minimally invasive medical devices targeted towards the cardiovascular, venous access, endosurgery, and oncology markets.
2. Licensing Royalties (Historical): Prior to 2016, Rex Medical licensed three vascular products (OptionELITE, CLEANER, UltraStream) to Argon Medical Devices through an exclusive agreement, generating licensing revenue. These products were sold to Argon Medical in January 2016.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Core offering

Rex Medical develops, manufactures, and markets the REVOLUTION™ Peripheral Atherectomy System, a low-profile rotational atherectomy catheter operating at 140,000 RPM with continuous mechanical aspiration for treating peripheral arterial disease above and below the knee. The device is sold to hospitals, outpatient surgery centers, and office interventional suites, with sale restricted by U.S. federal law to or on the order of a physician.

Product overview

Rex Medical is a single-product medical device company specializing in the REVOLUTION™ Peripheral Atherectomy System, an innovative rotational atherectomy device for treating peripheral arterial disease. The company focuses on cardiovascular applications with devices targeting the peripheral vasculature for atherectomy and thrombus removal procedures.

Differentiator

Problem solved

Functional benefit

Brands

• REVOLUTION: Peripheral Atherectomy System - an innovative low profile rotational atherectomy system (140,000 RPM) with continuous mechanical aspiration for below-the-knee (BTK) and above-the-knee (ATK) applications.

Products and services

• REVOLUTION™ Peripheral Atherectomy System Low-profile rotational atherectomy catheter operating at 140,000 RPM with continuous mechanical aspiration for treating peripheral arterial disease both above-the-knee (ATK) and below-the-knee (BTK). Indicated for atherectomy of peripheral vasculature and thrombus removal in patients with occlusive atherosclerotic disease, effective across thrombus, soft plaque, severely calcified lesions, and chronic total occlusions. Operates via a 72-watt laptop-sized power supply with no capital equipment required and minimal setup time, intended for interventional cardiologists, vascular surgeons, and interventional radiologists practicing in hospitals, outpatient surgery centers, and office interventional suites.

Quantifiable outcome

• 121 subjects successfully enrolled in REVEAL IDE clinical trial across 17 U.S. sites
• +2 more outcomes

Segments3 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

One partnership is on record.

• 17 U.S. Clinical Trial Sites (REVEAL IDE Study)coreStrategic or Co-development Partner · 19 March 2019Rex Medical partnered with 17 U.S. clinical trial sites to conduct the REVEAL Investigational Device Exemption (IDE) clinical study evaluating the safety and effectiveness of the Revolution Peripheral Atherectomy System. 121 patients were successfully enrolled across these sites for the study of infrainguinal lower extremity peripheral arterial occlusive disease treatment.

Scale indicators3 records

Recent moves5 records

Expansion highlights3 records

Emerging players

• Avinger: Avinger is a smaller, focused peripheral atherectomy company (Lumivascular/Ocelot/Tigereye OCT-guided atherectomy) targeting the same PAD/CLI market and interventional end-users as Rex Medical, but with imaging-guided differentiation.
• Inari Medical: Inari Medical develops catheter-based mechanical thrombectomy systems (FlowTriever, ClotTriever) for venous thromboembolism and peripheral applications, an emerging niche player whose mechanical aspiration approach is conceptually adjacent to Rex Medical's continuous mechanical aspiration design.

Broad incumbents

• Medtronic: Medtronic offers the HawkOne directional atherectomy system and a large peripheral vascular portfolio (IN.PACT, Endeavor), serving the same interventional customer base as Rex Medical but as part of a much broader cardiovascular franchise.
• Philips (Image-Guided Therapy): Philips acquired Volcano/CSI-adjacent atherectomy technology (Phoenix atherectomy) and bundles it with its IVUS/imaging franchise for peripheral vascular procedures, overlapping with Rex Medical's target indications and customers.
• BD (Becton Dickinson): BD's Peripheral Intervention franchise includes the Rotarex rotational thrombectomy/atherectomy device, directly competing with REVOLUTION™ in peripheral arterial and graft occlusions and serving the same vascular specialist customers.
• Boston Scientific: Boston Scientific is a major incumbent in peripheral vascular intervention with the Rotational Atherectomy System (formerly Pathway Medical, Jetstream) and a broad PV portfolio, competing with REVOLUTION™ while also serving other vascular and cardiac specialties.

Direct peers

• AngioDynamics: AngioDynamics offers peripheral thrombectomy and atherectomy products (e.g., AngioJet, Auryon) for treating PAD/DVT, competing head-to-head with Rex Medical in catheter-based peripheral vascular intervention.
• Argon Medical Devices: Argon Medical Devices acquired three vascular products from Rex Medical in 2016 (OptionELITE, CLEANER, UltraStream) and continues to market peripheral vascular and thrombectomy devices, making it both a former partner and direct competitive peer in the same peripheral vascular space.
• Cardiovascular Systems (CSI) / Abbott: CSI (acquired by Abbott in 2023) was the leading dedicated peripheral atherectomy company with orbital atherectomy systems (Diamondback, Stealth 360, JETstream) targeting infrainguinal PAD and CLI — the same indication and same interventional cardiology/vascular surgery customer base as Rex Medical's REVOLUTION™.
• Penumbra: Penumbra's Indigo thrombectomy system and peripheral vascular portfolio directly compete in the same peripheral arterial and venous mechanical thrombectomy/atherectomy space, selling to the same interventional radiologist and vascular surgeon customers Rex Medical targets.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

• Xx.com/Rex_Medical
• Facebookfacebook.com/Rex-Medica
• LinkedInlinkedin.com/company/rex-medical

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Rex Medical